Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Enterprise Value: 2010-2025

Historic Enterprise Value for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $344.2 million.

  • Lineage Cell Therapeutics' Enterprise Value rose 151.51% to $344.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.2 million, marking a year-over-year increase of 971.56%. This contributed to the annual value of $45.7 million for FY2024, which is 70.28% down from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Enterprise Value is $344.2 million, which was up 109.56% from $164.2 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Enterprise Value high stood at $392.2 million for Q2 2021, and its period low was $45.7 million during Q4 2024.
  • Moreover, its 3-year median value for Enterprise Value was $163.7 million (2023), whereas its average is $167.7 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Enterprise Value skyrocketed by 262.03% in 2021, and later crashed by 76.99% in 2025.
  • Lineage Cell Therapeutics' Enterprise Value (Quarterly) stood at $353.3 million in 2021, then crashed by 71.60% to $100.3 million in 2022, then skyrocketed by 53.35% to $153.8 million in 2023, then tumbled by 70.28% to $45.7 million in 2024, then spiked by 151.51% to $344.2 million in 2025.
  • Its Enterprise Value stands at $344.2 million for Q3 2025, versus $164.2 million for Q2 2025 and $53.8 million for Q1 2025.